Balyasny Asset Management LLC Novo Nordisk A S Call Options Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $26.3 Million - $31.6 Million	300,000 New	300,000 $31 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $14.2 Million - $15.7 Million	91,000 New	91,000 $14.7 Million
Q3 2021 Nov 15, 2021	SELL	$84.42 - $106.62 $11 Million - $13.9 Million	-130,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$67.66 - $84.76 $28.4 Million - $35.6 Million	-420,000 Reduced 76.36%	130,000 $10.9 Million
Q4 2019 Feb 14, 2020	BUY	$49.86 - $58.26 $17.5 Million - $20.4 Million	350,000 Added 175.0%	550,000 $31.8 Million
Q3 2019 Nov 14, 2019	BUY	$47.54 - $53.43 $950,800 - $1.07 Million	20,000 Added 11.11%	200,000 $10.3 Million
Q4 2018 Feb 14, 2019	SELL	$41.54 - $47.25 $1.25 Million - $1.42 Million	-30,000 Reduced 14.29%	180,000 $8.29 Million
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $8.65 Million - $9.48 Million	-185,000 Reduced 46.84%	210,000 $9.9 Million
Q2 2018 Aug 14, 2018	BUY	$44.29 - $50.42 $17.5 Million - $19.9 Million	395,000 New	395,000 $18.2 Million

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $198B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.